Portman Square Capital’s BridgeBio Pharma BBIO Stock Holding History

Portman Square Capital’s Portfolio BBIO Stock Details BBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-117,826	Closed	-$7.73M	–	118
2025 Q3	$6.12M	Sell	117,826 -27,867	-19%	-$1.36M	0.27%	58
2025 Q2	$6.29M	Buy	145,693 +6,446	+5%	+$234K	0.18%	109
2025 Q1	$4.81M	Buy	139,247 +114,720	+468%	+$3.87M	0.13%	160
2024 Q4	$673K	Sell	24,527 -52,760	-68%	-$1.36M	0.02%	230
2024 Q3	$1.97M	Buy	77,287 +29,110	+60%	+$764K	0.07%	228
2024 Q2	$1.22M	Sell	48,177 -29,453	-38%	-$805K	0.04%	271
2024 Q1	$2.4M	Buy	77,630 +49,951	+180%	+$1.7M	0.07%	191
2023 Q4	$1.12M	Sell	27,679 -192,918	-87%	-$5.79M	0.03%	345
2023 Q3	$5.82M	Buy	+220,597	New	+$6.26M	0.14%	166

Other funds holding BBIO

YIH

Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return

Tema ETFs New York $3.09B AUM 72.72% 1-Year Est. Return

Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return

ORI

Oak Ridge Investments Chicago, Illinois $1.77B AUM 63.16% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return

WMA

Wealth Management Associates Cherry Hill, New Jersey $362M AUM 33.28% 1-Year Est. Return

QCM

QRG Capital Management Chicago, Illinois $12.1B AUM 44.98% 1-Year Est. Return

FBT

First Bank & Trust Brookings, South Dakota $680M AUM 25.36% 1-Year Est. Return

Perpetual Ltd Sydney, New South Wales, Australia $7B AUM 19.75% 1-Year Est. Return

Portman Square Capital's BBIO Position: Q4 2025 in Review

Portman Square Capital sold out of BridgeBio Pharma (BBIO) in Q4 2025, closing a stake of 117,826 shares — an estimated $7.73M sold.

Portman Square Capital first reported a position in BBIO in Q3 2023 and held it in 9 quarters. The position peaked at $6.29M in Q2 2025. 432 funds tracked by Wall St. Rank hold BBIO as of Q4 2025.

Portman Square Capital reported no remaining BridgeBio Pharma position as of Q4 2025 after selling out during the quarter.
Portman Square Capital sold 117,826 BridgeBio Pharma shares in Q4 2025, an estimated $7.73M.
Portman Square Capital first reported a position in BridgeBio Pharma in Q3 2023 and held it in 9 quarters.
Portman Square Capital's BridgeBio Pharma position peaked at $6.29M in Q2 2025.
432 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q4 2025.

Based on Portman Square Capital's 13F filing for Q4 2025, filed 23 Jan 2026.